Merger cash-out: Avidity Biosciences (RNA) director records share disposals
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Avidity Biosciences director Edward M. Kaye, MD reported multiple dispositions of stock options and common shares to the company in connection with its acquisition by Novartis. The filing shows stock options and common stock were transferred to the issuer under a merger agreement with Novartis and Ajax Acquisition Sub.
According to the footnotes, the common shares (including those underlying previously reported restricted stock units) were disposed of pursuant to the Agreement and Plan of Merger dated October 25, 2025. The reported stock options were cashed out for a payment equal to the excess of the merger consideration of $72.00 per share over their exercise prices.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Kaye Edward M. MD
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 10,034 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 13,489 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 11,323 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 9,534 | $0.00 | -- |
| Disposition | Common Stock | 6,692 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (1)
- The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
FAQ
What does the latest Form 4 for Avidity Biosciences (RNA) report?
The Form 4 reports that director Edward M. Kaye, MD disposed of stock options and common shares to the issuer. These transactions occurred in connection with Avidity Biosciences’ merger with Novartis, under an Agreement and Plan of Merger dated October 25, 2025.
How were Avidity Biosciences (RNA) stock options treated in the Novartis merger?
The reported stock options were disposed of and exchanged for cash under the merger agreement. Each option generated a cash payment equal to the excess of the merger consideration of $72.00 per share over its exercise price, effectively cashing out the in-the-money value.
What common stock transactions did Edward M. Kaye report for Avidity Biosciences (RNA)?
He reported a disposition of common stock, including shares issuable from previously reported restricted stock units. The shares were transferred pursuant to the terms of the merger agreement among Novartis, Ajax Acquisition Sub, Inc., and Avidity Biosciences, as part of the overall acquisition structure.
Who is the insider in this Avidity Biosciences (RNA) Form 4 filing?
The insider is Edward M. Kaye, MD, who is identified as a director of Avidity Biosciences. The filing shows his direct ownership saw multiple issuer-directed dispositions of both stock options and common shares linked to completion of the Novartis merger transaction.
What is the merger consideration mentioned in the Avidity Biosciences (RNA) Form 4?
The Form 4 footnotes state a merger consideration of $72.00 per share. This amount was used to calculate cash payments for the disposed stock options, with holders receiving the difference between $72.00 and each option’s exercise price, where that difference was positive.
Are the reported Avidity Biosciences (RNA) dispositions open-market sales?
No, the transactions are classified as dispositions to the issuer rather than open-market sales. They occurred under the merger agreement with Novartis, where stock options and common shares were surrendered or converted as part of the acquisition consideration structure.